论文部分内容阅读
自1983年重组白细胞介素2(rLL-2)问世以来,作为肿瘤生物疗法之一的过继性细胞免疫治疗(adoptive cellular immunotherapy,AIT)取得了迅速发展,淋巴因子激活杀伤细胞(LAK)是第一
Since the advent of recombinant interleukin 2 (rLL-2) in 1983, rapid advances have been made in adoptive cellular immunotherapy (AIT), one of the tumor biotherapies, in which lymphokine-activated killer cells (LAKs) one